• Link to Facebook
  • Link to Instagram
  • Link to X
  • Home
  • Members
  • En Español
  • Contact
National Cancer Institute Clinical Oncology Research Program
SCOR - Southeast Clinical Oncology Research Consortium
  • Clinical Trials
  • Find a Doctor
  • About SCOR
    • Become a Member
  • Resources
    • Videos
    • Articles
    • Community Members
    • Community Support Groups
    • FAQs
    • Patient Resources
  • Menu Menu
  • Home
  • Members
  • En Español
  • Clinical Trials
  • Find a Clinical Trial Doctor
  • About SCOR
    • About SCOR
    • Become a Member of SCOR
  • Resources
    • Videos
    • News
    • Community Members
    • Community Support Groups
    • Clinical Trials FAQ
    • Clinical Trial Patient Resources
  • Contact SCOR
  • Privacy Policy
  • Site Map
Olivera Finn immunologist cancer vaccine

Pursuing a Cancer Prevention Vaccine

August 18, 2021/in Cancer, Cancer Clinical Trial, Cancer Research, Cancer Vaccines, Clinical Research, Clinical Trial

For more than two decades, Olivera Finn has tirelessly pursued one goal in her research: to develop a vaccine to prevent cancer. She has had this goal since 1989, when her research team discovered the first tumor antigen recognized by a type of immune cell that can kill cancer cells. That antigen—an abnormal version of a protein called MUC1—is produced by the cells of more than 80% of cancer types, including cancers of the breast, pancreas, colon, lung, and prostate.

Although she started her research career as an organ transplant immunologist, the discovery of MUC1 was a pivotal point in Olivera’s career trajectory. “Once we discovered tumor antigens,” she said, “I never looked back.” Olivera received her first NCI grant in 1991 and has been funded ever since to study the biology of tumor antigens and develop them as targets for cancer prevention.

Cancer can take many years—even decades—to develop. Some cancers arise from precursor growths that can be detected by current screening methods. For example, colorectal polyps called advanced adenomas, which can be detected by colonoscopy, can progress to colorectal cancer. These adenomas can be removed surgically, but in many patients, new ones continue to develop and some will become malignant. Olivera’s lab found that the cells of advanced adenomas and the precursors of pancreatic, lung, and many other types of cancer all produce abnormal MUC1 protein.

The presence of abnormal MUC1 on premalignant growths may make it a good target for a vaccine that would prevent their progression to cancer or the development of new precursors. To test this idea, Olivera’s group conducted the first ever clinical trial of a cancer prevention vaccine based on a tumor antigen in healthy people without cancer who were at increased risk of developing the disease.

In the NCI-funded trial, reported in 2013, individuals with a history of advanced adenomas were given an MUC1 vaccine. The vaccine was shown to be safe and to elicit a strong immune response and a long-lasting immune memory. NCI is currently sponsoring a phase II trial testing whether the vaccine will prevent the regrowth of colorectal polyps.

Looking forward, Olivera envisions, “If you are in your 60s and your doctor discovers you are at high risk for cancer, the idea would be to vaccinate to boost the immune system’s ability to keep any abnormal cells in check instead of waiting to see if cancer develops.”

Olivera says that funding from NCI is critical for her research and for cancer prevention research in general. Cancer prevention research is complex, and translating laboratory discoveries into new ways to prevent cancer requires sustained investments over many years—investments that the private sector is often reluctant to make. But “building the evidence that vaccines are an effective way of controlling cancer will go a long way toward getting companies interested,” she said.

The field of cancer immunology has expanded dramatically and has led to immunotherapies for the treatment of advanced cancers as well as vaccines against some viruses that cause cancer. Boosting the immune system to prevent cancers that are not caused by viruses may now be within reach. “The opportunities are amazing,” she added.

Pursuing a Cancer Prevention Vaccine was originally published by the National Cancer Institute in September, 2017

 

Share this entry
  • Share on Facebook
  • Share on X
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://southeastclinicaloncology.org/wp-content/uploads/2021/08/Olivera-Finn.jpg 1349 899 BCeditor https://southeastclinicaloncology.org/wp-content/uploads/2018/06/SCOR-Southeast-Clinical-Oncology-Research_Logo.png BCeditor2021-08-18 10:40:252021-08-18 10:40:25Pursuing a Cancer Prevention Vaccine
You might also like
What is a Clinical Trial?
Dynamic Duo in Pinehurst Appreciates Opportunity to Participate in Clinical Trial
May is Skin Cancer Awareness Month
Treating Prostate Cancer Close to Home
Accelerating Progress with the Power of Data
Patient Safety in Clinical Trials
Sanford’s Cook is the First to Undergo Procedure to “Zap” Lung Cancer
FirstHealth Is World Leader in Lung Cancer Care Through Use of Robotic Technology

A program of the National Cancer Institute of the National Institutes of Health

Community Resources

FAQ's

Participating SCOR Members

  • Cary, NC
  • Charleston, SC
  • Charlotte, NC
  • Chesapeake, VA
  • Florence, SC
  • Fort Myers, FL
  • Gastonia, NC
  • Goldsboro, NC
  • Greensboro, NC
  • Hendersonville, NC – Pardee
  • Hendersonville, NC – Advent Health
  • Kingsport, TN
  • Martinsville, VA
  • New Bern, NC
  • Pinehurst, NC
  • Richmond, VA
  • Rocky Mount, NC
  • Savannah, GA
  • Wilmington, NC
  • Winston Salem, NC

Contact SCOR

Southeast Clinical Oncology
Research Consortium

2150 Country Club Road,
Suite 200
Winston Salem, NC 27104
T: (336) 448-1417
F: (336) 448-1425

Member Communities

Cary, NC
Charleston, SC
Charlotte, NC
Chesapeake, VA
Florence, SC
Fort Myers, FL
Gastonia, NC
Goldsboro, NC
Greensboro, NC
Hendersonville, NC – Pardee
Hendersonville, NC – AdventHealth
Kingsport, TN
Martinsville, VA
New Bern, NC
Pinehurst, NC
Richmond, VA
Rocky Mount, NC
Savannah, GA
Syracuse, NY
Wilmington, NC
Winston-Salem, NC

National Cancer Institute Clinical Oncology Research Program, Grant #5UG1CA-189858. All content © Southeast Clinical Oncology Research Consortium. All rights reserved. 2150 Country Club Road, Suite 200, Winston-Salem, NC 27104-4241 | Phone: (336) 448-1417 | Fax: (336) 448-1425 | Site Map | Privacy Policy | Website Design by Built Creative.
  • Link to Facebook
  • Link to Instagram
  • Link to X
Link to: Childhood Cancer Link to: Childhood Cancer Childhood CancerChildhood Cancer Awareness Month SCOR Link to: Advances in Prostate Cancer Research Link to: Advances in Prostate Cancer Research Advances in Prostate Cancer Research
Scroll to top Scroll to top Scroll to top